IMI/REL (MK-7655A) vs. CMS + IMI in Subjects with Imipenem-Resistant Bacterial Infection (1) To estimate the proportion of subjects with favorable overall response to IMI/MK-7655 (Treatment Group 1 only) and to CMS + IMI (Treatment Group 2). The overall response will be estimated based o...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma To define the objective response rate associated with the administration of vorinostat in combination with bortezomib to patients with relapsed or refractory multiple myeloma after at least 2 prior tr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Maintenance of Anemia Treatment in Patients With Chronic Kidney Disease Who are on Hemodialysis E.2.1 Main objective: To define optimal factor (e.g. μg MK-2578 per U epoetin) for conversion of epoetin alfa or epoetin beta administered three times weekly (TIW), two times weekly (BIW), or week...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Pediatric Asthma Safety Study To estimate the effects on HPA axis function for MF/F MDI 50/10 mcg, 100/10 mcg and 200/10 mcg twice daily (BID) in plasma cortisol AUC(0-24 hours) as compared to montelukast 5 mg once daily (QD) (4 m...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus in Men With Asymptomatic, Metastatic Castrate-Resistant Prostate Cancer To determine the efficacy of the combination of ridaforolimus and bicalutamide compared to placebo and bicalutamide by PSA decline within 12 weeks, a surrogate measurement of overall survival efficacy...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study in adults who have ongoing asthma, using a new product combined with Montelukast The purpose of this study is to assess the efficacy and safety of MK-1029, compared with placebo, in subjects aged 18 to 75 years with evidence of asthma uncontrolled on montelukast, using measures of...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations To determine the efficacy of deforolimus in patients with KRAS mutant NSCLC who have progressed after two prior chemotherapy regimens compared to placebo by progression free survival analysis of ran...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients with Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart Disease In high risk patients for CHD with metabolic syndrome and hypercholesterolemia, to evaluate the LDL-C lowering efficacy of the ezetimibe/simvastatin combination tablet compared to atorvastatin.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase IIb, Randomized, Active Comparator-Controlled, Open-Label Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Treatment of Anemia in ESA (Erythropoiesis-Stimulating Agent)-Naive Patients with Chronic Kidney Disease Who are Not on Dialysis 1) To define the effective starting dose(s) for subcutaneous administration of MK-2578 to anemic patients with CKD who are not on dialysis and who are ESA naive. 2) To assess the safety and tolerabi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Assess the effect of switching HIV-1 infected subjects with CNS toxicity (≥ Grade 2) from ATRIPLA™ or its complements to MK-1439A To evaluate the effect of a switch to MK-1439A compared with continuation of ATRIPLA on the incidence of Grade 2 or worse CNS toxicity (defined as at least one toxicity listed on the CNS toxicity ques...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune